Collectively, these results suggest that combination of αCD4 and low-dose HMGN1 (in the range of 0.08 to 0.4 μg per injection), brings T-cell dependent anti-tumor effects in mouse subcutaneous tumor models and has an ability to develop immunological memory against tumor cells. The gene discussed is HMGN1; the disease is neoplasm.